Your browser doesn't support javascript.
loading
Survival Outcomes in Octogenarian and Nonagenarian Patients Treated with First-line Androgen Deprivation Therapy for Organ-confined Prostate Cancer.
Dell'Oglio, Paolo; Bishr, Mohamed; Boehm, Katharina; Trudeau, Vincent; Larcher, Alessandro; Tian, Zhe; Sosa, Josè; Moschini, Marco; Saad, Fred; Capitanio, Umberto; Briganti, Alberto; Graefen, Markus; Montorsi, Francesco; Karakiewicz, Pierre I.
Afiliación
  • Dell'Oglio P; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada; Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. Electronic address: paolo.delloglio@gmail.com.
  • Bishr M; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada; Department of Urology, University of Montreal Health Center, Montreal, Canada.
  • Boehm K; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada; Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany.
  • Trudeau V; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada; Department of Urology, University of Montreal Health Center, Montreal, Canada.
  • Larcher A; Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Tian Z; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada.
  • Sosa J; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada.
  • Moschini M; Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Saad F; Department of Urology, University of Montreal Health Center, Montreal, Canada.
  • Capitanio U; Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Briganti A; Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Graefen M; Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany.
  • Montorsi F; Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Karakiewicz PI; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada; Department of Urology, University of Montreal Health Center, Montreal, Canada.
Eur Urol Focus ; 4(6): 834-841, 2018 12.
Article en En | MEDLINE | ID: mdl-28753853
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Orquiectomía / Hormona Liberadora de Gonadotropina / Antagonistas de Andrógenos Tipo de estudio: Guideline / Prognostic_studies Aspecto: Patient_preference Límite: Aged80 / Humans / Male Idioma: En Revista: Eur Urol Focus Año: 2018 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Orquiectomía / Hormona Liberadora de Gonadotropina / Antagonistas de Andrógenos Tipo de estudio: Guideline / Prognostic_studies Aspecto: Patient_preference Límite: Aged80 / Humans / Male Idioma: En Revista: Eur Urol Focus Año: 2018 Tipo del documento: Article Pais de publicación: Países Bajos